How to buy Lantern Pharma stock (LTRN)

Lantern Pharma is a biotechnology business based in the US. Lantern Pharma shares (LTRN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.13 – a decrease of 2.65% over the previous week. Lantern Pharma employs 21 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Lantern Pharma stock

Buy Lantern Pharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Lantern Pharma stock price (NASDAQ: LTRN)

Use our graph to track the performance of LTRN stocks over time.

Lantern Pharma shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$3.13
52-week range	$2.79 - $11.99
50-day moving average more info button	$3.43
200-day moving average more info button	$4.90
Wall St. target price	$20.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.78

Is it a good time to buy Lantern Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lantern Pharma price performance over time

Historical closes compared with the close of $3.125 from 2024-12-24

1 week (2024-12-19)	-2.65%
1 month (2024-11-27)	0.48%
3 months (2024-09-26)	-18.62%
6 months (2024-06-26)	-26.81%

1 year (2023-12-26)	-23.41%
2 years (2022-12-23)	-44.40%
3 years (2021-12-23)	7.31
5 years (2019-12-23)	N/A

Lantern Pharma financials

Gross profit TTM	$0
Return on assets TTM	-28.07%
Return on equity TTM	-44.82%
Profit margin	0%
Book value	$3.82
Market Capitalization more info button	$34.6 million

TTM: trailing 12 months

Lantern Pharma share dividends

We're not expecting Lantern Pharma to pay a dividend over the next 12 months.

Lantern Pharma share price volatility

Over the last 12 months, Lantern Pharma's shares have ranged in value from as little as $2.79 up to $11.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lantern Pharma's is 1.567. This would suggest that Lantern Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Lantern Pharma overview

Lantern Pharma Inc. , a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc.

Frequently asked questions

What percentage of Lantern Pharma is owned by insiders or institutions?
Currently 14.745% of Lantern Pharma shares are held by insiders and 24.103% by institutions. How many people work for Lantern Pharma?
Latest data suggests 21 work at Lantern Pharma. When does the fiscal year end for Lantern Pharma?
Lantern Pharma's fiscal year ends in December. Where is Lantern Pharma based?
Lantern Pharma's address is: 1920 McKinney Avenue, Dallas, TX, United States, 75201 What is Lantern Pharma's ISIN number?
Lantern Pharma's international securities identification number is: US51654W1018